文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

双能CT预测乳腺癌新辅助化疗后腋窝淋巴结状态

Predict status of axillary lymph node after neoadjuvant chemotherapy with dual-energy CT in breast cancer.

作者信息

Wang Zhen, Fan Zhao-Qing, Wang Li-Ze, Cao Kun, Long Rong, Luo Yao, Li Xiao-Ting, You Liang, Li Qing-Yang, Sun Ying-Shi

机构信息

Department of Radiology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, No. 52 Fu Cheng Rd, Hai Dian District, Beijing, 100142, China.

Breast Cancer Center, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute, No. 52 Fu Cheng Rd, Hai Dian District, Beijing, 100142, China.

出版信息

BMC Med Imaging. 2025 Jul 1;25(1):233. doi: 10.1186/s12880-025-01799-7.


DOI:10.1186/s12880-025-01799-7
PMID:40597006
Abstract

BACKGROUND: A proportion of breast patients achieve axillary pathological complete response (pCR) following NAC. However, few studies have investigated the potential of quantitative parameters derived from dual-energy CT (DECT) for predicting axillary lymph node (ALN) downstaging after NAC. METHODS: This study included a prospective training and retrospective validation cohort from December 2019 to June 2022. Both groups enrolled invasive breast cancer with biopsy-proved metastatic ALNs who underwent contrast-enhanced DECT and NAC followed by surgery. A metastatic ALN, named target lymph node (TLN), was marked with metal clip at baseline. Quantitative DECT parameters and size of TLN, and clinical information were compared between pCR and non-pCR node group referring to postoperative pathology. Three predictive models, clinical, quantitative CT, and combinational models, were built by logistic regression and nomogram was drawn accordingly. The performance was evaluated by the receiver operator characteristic curve and clinical usefulness was assessed by decision curve analysis. RESULTS: A total of 75 and 53 patients were included in training and validation cohort respectively. Of them, 34 (45.3%) and 22 (41.5%) patients achieved nodal pCR in the two sets. Multivariable analyses revealed that negative estrogen receptor expression, parenchyma thickness and the iodine concentration of TLN at post-NAC CT were independently predictive factors for pCR. The combinational model showed discriminatory power than the single clinical model (AUC, 0.724; p = 0.003) and quantitative CT model (AUC, 0.728; p = 0.030) with AUC of 0.847 and 0.828 in training and validation cohort. It provided enhanced net benefits within a wide range of threshold probabilities. CONCLUSION: Quantitative DECT parameters can be used to evaluate axillary nodal status after NAC and guide personalized treatment strategies.

摘要

背景:一部分乳腺癌患者在新辅助化疗(NAC)后实现腋窝病理完全缓解(pCR)。然而,很少有研究探讨双能CT(DECT)衍生的定量参数预测NAC后腋窝淋巴结(ALN)降期的潜力。 方法:本研究纳入了2019年12月至2022年6月的前瞻性训练队列和回顾性验证队列。两组均纳入经活检证实有转移性ALN的浸润性乳腺癌患者,这些患者接受了对比增强DECT和NAC,随后进行手术。在基线时用金属夹标记一个转移性ALN,称为靶淋巴结(TLN)。根据术后病理,比较pCR组和非pCR组TLN的DECT定量参数、大小及临床信息。通过逻辑回归建立了三种预测模型,即临床模型、定量CT模型和联合模型,并据此绘制列线图。通过受试者工作特征曲线评估模型性能,通过决策曲线分析评估临床实用性。 结果:训练队列和验证队列分别纳入75例和53例患者。其中,两组分别有34例(45.3%)和22例(41.5%)患者实现淋巴结pCR。多变量分析显示,雌激素受体阴性表达、NAC后CT上TLN的实质厚度和碘浓度是pCR的独立预测因素。联合模型在训练队列和验证队列中的曲线下面积(AUC)分别为0.847和0.828,显示出比单一临床模型(AUC,0.724;p = 0.003)和定量CT模型(AUC,0.728;p = 0.030)更强的鉴别能力。在广泛的阈值概率范围内,联合模型提供了更高的净效益。 结论:DECT定量参数可用于评估NAC后腋窝淋巴结状态并指导个性化治疗策略。

相似文献

[1]
Predict status of axillary lymph node after neoadjuvant chemotherapy with dual-energy CT in breast cancer.

BMC Med Imaging. 2025-7-1

[2]
The development and validation of a risk stratification system for assessing axillary status after neoadjuvant therapy in node-positive breast cancer: a multicenter, prospective, observational study.

Int J Surg. 2025-6-1

[3]
A Multicenter Cohort Study on Ultrasound-based Deep Learning Nomogram for Predicting Post-Neoadjuvant Chemotherapy Axillary Lymph Node Status in Breast Cancer Patients.

Acad Radiol. 2025-3

[4]
Diagnostic performance of MRI for assessing axillary lymph node status after neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis.

Eur Radiol. 2024-2

[5]
Positron emission tomography (PET) and magnetic resonance imaging (MRI) for the assessment of axillary lymph node metastases in early breast cancer: systematic review and economic evaluation.

Health Technol Assess. 2011-1

[6]
Changing practice patterns in axillary management for patients with node-positive breast cancer towards increased use of sentinel lymph node biopsy-alone after neoadjuvant chemotherapy: results of a survey (MF17-01) among Turkish surgeons.

Langenbecks Arch Surg. 2025-6-16

[7]
A non-invasive artificial intelligence model for identifying axillary pathological complete response to neoadjuvant chemotherapy in breast cancer: a secondary analysis to multicenter clinical trial.

Br J Cancer. 2024-9

[8]
Nomogram for Predicting Pathological Complete Response after Neoadjuvant Chemotherapy in Operable Primary Breast Cancer.

J Coll Physicians Surg Pak. 2025-3

[9]
Development and Validation of an Ultrasound and Clinicopathological Features-Based Nomogram for Predicting Non-Sentinel Lymph Node Metastasis in Breast Cancer Patients: A Single-Center Observational Study.

J Clin Ultrasound. 2025-6

[10]
Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.

Health Technol Assess. 2006-9

本文引用的文献

[1]
Safety of Targeted Axillary Dissection After Neoadjuvant Therapy in Patients With Node-Positive Breast Cancer.

JAMA Surg. 2023-8-1

[2]
Prediction of Residual Axillary Nodal Metastasis Following Neoadjuvant Chemotherapy for Breast Cancer: Radiomics Analysis Based on Chest Computed Tomography.

Korean J Radiol. 2023-6

[3]
Clinical feasibility and oncological safety of non-radioactive targeted axillary dissection after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: a prospective diagnostic and prognostic study.

Int J Surg. 2023-7-1

[4]
Detection of axillary lymph node metastasis in breast cancer using dual-layer spectral computed tomography.

Front Oncol. 2022-10-10

[5]
Correlation of CT-data derived from multiparametric dual-layer CT-maps with immunohistochemical biomarkers in invasive breast carcinomas.

Eur J Radiol. 2022-11

[6]
Accuracy of ultrasonographic changes during neoadjuvant chemotherapy to predict axillary lymph node response in clinical node-positive breast cancer patients.

Front Oncol. 2022-7-22

[7]
Application of machine learning with multiparametric dual-energy computed tomography of the breast to differentiate between benign and malignant lesions.

Quant Imaging Med Surg. 2022-1

[8]
Possibility to discriminate benign from malignant breast lesions detected on dual-layer spectral CT-evaluation.

Eur J Radiol. 2021-9

[9]
Dual-energy CT quantitative parameters for the differentiation of benign from malignant lesions and the prediction of histopathological and molecular subtypes in breast cancer.

Quant Imaging Med Surg. 2021-5

[10]
Breast cancer: comparison of quantitative dual-layer spectral CT and axillary ultrasonography for preoperative diagnosis of metastatic axillary lymph nodes.

Eur Radiol Exp. 2021-4-9

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索